BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance

Cancer Cell

Volumn 20, Issue 6, 2011, Pages 797-809

  Drost, Rinske ^a   Bouwman, Peter ^a   Rottenberg, Sven ^a   Boon, Ute ^a   Schut, Eva ^a   Klarenbeek, Sjoerd ^a   Klijn, Christiaan ^a   van der Heijden, Ingrid ^a   van der Gulden, Hanneke ^a   Wientjens, Ellen ^a   Pieterse, Mark ^a   Catteau, Aurelie ^b   Green, Pete ^b   Solomon, Ellen ^b   Morris, Joanna R ^b,c   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NIMUSTINE; OLAPARIB; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; FEMALE; GENE MUTATION; MISSENSE MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 83455229693     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.11.014     Document Type: Article

References (57)

1. Asakawa H., Koizumi H., Koike A., Takahashi M., Wu W., Iwase H., Fukuda M., Ohta T. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res. 2010, 12:R17.
2. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 2000, 275:23899-23903.
3. Bouwman P., Aly A., Escandell J.M., Pieterse M., Bartkova J., van der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17:688-695.
4. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
5. Brzovic P.S., Meza J.E., King M.C., Klevit R.E. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J. Biol. Chem. 2001, 276:41399-41406.
6. Brzovic P.S., Keeffe J.R., Nishikawa H., Miyamoto K., Fox D., Fukuda M., Ohta T., Klevit R. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc. Natl. Acad. Sci. USA 2003, 100:5646-5651.
7. Castilla L.H., Couch F.J., Erdos M.R., Hoskins K.F., Calzone K., Garber J.E., Boyd J., Lubin M.B., Deshano M.L., Brody L.C., et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat. Genet. 1994, 8:387-391.
8. Chang S., Biswas K., Martin B.K., Stauffer S., Sharan S.K. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J. Clin. Invest. 2009, 119:3160-3171.
9. Christensen D.E., Brzovic P.S., Klevit R.E. E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat. Struct. Mol. Biol. 2007, 14:941-948.
10. de Ronde J.J., Klijn C., Velds A., Holstege H., Reinders M.J., Jonkers J., Wessels L.F. KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data. BMC Res. Notes 2010, 3:298.
11. Deans A.J., West S.C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 2011, 11:467-480.
12. Drost R.M., Jonkers J. Preclinical mouse models for BRCA1-associated breast cancer. Br. J. Cancer 2009, 101:1651-1657.
13. Evers B., Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006, 25:5885-5897.
14. Evers B., Schut E., van der Burg E., Braumuller T.M., Egan D.A., Holstege H., Edser P., Adams D.J., Wade-Martins R., Bouwman P., Jonkers J. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res. 2010, 16:99-108.
15. Fabbro M., Rodriguez J.A., Baer R., Henderson B.R. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J. Biol. Chem. 2002, 277:21315-21324.
16. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
17. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
18. Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C., De Greve J., Lubinski J., Shanley S., Messiou C., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010, 28:2512-2519.
19. Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., King M.C. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 1994, 8:399-404.
20. Graeser M., McCarthy A., Lord C.J., Savage K., Hills M., Salter J., Orr N., Parton M., Smith I.E., Reis-Filho J.S., et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 2010, 16:6159-6168.
21. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y., Ogata H., Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 2001, 276:14537-14540.
22. Hohenstein P., Kielman M.F., Breukel C., Bennett L.M., Wiseman R., Krimpenfort P., Cornelisse C., van Ommen G.J., Devilee P., Fodde R. A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 2001, 20:2544-2550.
23. Holstege H., van Beers E., Velds A., Liu X., Joosse S.A., Klarenbeek S., Schut E., Kerkhoven R., Klijn C.N., Wessels L.F., et al. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer 2010, 10:455.
24. Huen M.S., Sy S.M., Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 2010, 11:138-148.
25. Ishida S., McCormick F., Smith-McCune K., Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
26. Joukov V., Chen J., Fox E.A., Green J.B., Livingston D.M. Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc. Natl. Acad. Sci. USA 2001, 98:12078-12083.
27. Klijn C., Holstege H., de Ridder J., Liu X., Reinders M., Jonkers J., Wessels L. Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res. 2008, 36:e13.
28. Lakhani S.R., Van De Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., Easton D.F. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 2002, 20:2310-2318.
29. Lips E.H., Mulder L., Hannemann J., Laddach N., Vrancken Peeters M.T., van de Vijver M.J., Wesseling J., Nederlof P.M., Rodenhuis S. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann. Oncol. 2011, 22:870-876.
30. Liu X., Holstege H., van der Gulden H., Treur-Mulder M., Zevenhoven J., Velds A., Kerkhoven R.M., van Vliet M.H., Wessels L.F., Peterse J.L., et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 2007, 104:12111-12116.
31. Mallery D.L., Vandenberg C.J., Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J. 2002, 21:6755-6762.
32. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
33. Morris J.R., Solomon E. BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum. Mol. Genet. 2004, 13:807-817.
34. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell 1999, 4:511-518.
35. Moynahan M.E., Cui T.Y., Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001, 61:4842-4850.
36. Nelson A.C., Holt J.T. Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage. Radiat. Res. 2010, 174:1-13.
37. Rahman N., Stratton M.R. The genetics of breast cancer susceptibility. Annu. Rev. Genet. 1998, 32:95-121.
38. Ransburgh D.J., Chiba N., Ishioka C., Toland A.E., Parvin J.D. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res. 2010, 70:988-995.
39. Reid L.J., Shakya R., Modi A.P., Lokshin M., Cheng J.T., Jasin M., Baer R., Ludwig T. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc. Natl. Acad. Sci. USA 2008, 105:20876-20881.
40. Rottenberg S., Nygren A.O., Pajic M., van Leeuwen F.W., van der Heijden I., van de Wetering K., Liu X., de Visser K.E., Gilhuijs K.G., van Tellingen O., et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 2007, 104:12117-12122.
41. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., Derksen P.W., de Bruin M., Zevenhoven J., Lau A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 2008, 105:17079-17084.
42. Rottenberg S., Pajic M., Jonkers J. Studying drug resistance using genetically engineered mouse models for breast cancer. Methods Mol. Biol. 2010, 596:33-45.
43. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. USA 2001, 98:5134-5139.
44. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
45. Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J., Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009, 69:6381-6386.
46. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., Stanbridge E.J., Lee E.Y. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008, 68:3243-3250.
47. Shakya R., Reid L.J., Reczek C.R., Cole F., Egli D., Lin C.S., deRooij D.G., Hirsch S., Ravi K., Hicks J.B., et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011, 334:525-528.
48. Shakya R., Szabolcs M., McCarthy E., Ospina E., Basso K., Nandula S., Murty V., Baer R., Ludwig T. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc. Natl. Acad. Sci. USA 2008, 105:7040-7045.
49. Swisher E.M., Sakai W., Karlan B.Y., Wurz K., Urban N., Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008, 68:2581-2586.
50. Taniguchi T., Garcia-Higuera I., Andreassen P.R., Gregory R.C., Grompe M., D'Andrea A.D. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420.
51. Tirkkonen M., Johannsson O., Agnarsson B.A., Olsson H., Ingvarsson S., Karhu R., Tanner M., Isola J., Barkardottir R.B., Borg A., Kallioniemi O.P. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997, 57:1222-1227.
52. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
53. Vandenberg C.J., Gergely F., Ong C.Y., Pace P., Mallery D.L., Hiom K., Patel K.J. BRCA1-independent ubiquitination of FANCD2. Mol. Cell 2003, 12:247-254.
54. Vollebergh M.A., Lips E.H., Nederlof P.M., Wessels L.F., Schmidt M.K., van Beers E.H., Cornelissen S., Holtkamp M., Froklage F.E., de Vries E.G., et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 2011, 22:1561-1570.
55. Xia Y., Pao G.M., Chen H.W., Verma I.M., Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Biol. Chem. 2003, 278:5255-5263.
56. Xu X., Qiao W., Linke S.P., Cao L., Li W.M., Furth P.A., Harris C.C., Deng C.X. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 2001, 28:266-271.
57. Zhu Q., Pao G.M., Huynh A.M., Suh H., Tonnu N., Nederlof P.M., Gage F.H., Verma I.M. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011, 477:179-184.